Adverse drug reactions associated with immune checkpoint inhibitors: An exploratory nested case-control study in a historical cohort

Pluye, Manon; Gouraud, Aurore; Hervé, Magali; Le, Ha; Dagonneau, Tristan; Dalle, Stéphane; Cottin, Judith; Cucherat, Michel; Atzenhoffer, Marina

doi:10.1016/j.therap.2022.07.001

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some adverse drug reactions are associated with ICIs ( 32 , 33 ). In this study, no obvious adverse reactions occurred in all patients in the observation group.…”

Section: Discussionmentioning

confidence: 99%

Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study

Wang,

Zhu,

Zhou

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background It has remained unclear how programmed cell death ligand 1 (PD-L1) inhibitors affect peripheral blood lymphocyte (PBL) subsets in patients with advanced non-small cell lung cancer (NSCLC). This study assessed the predictive and prognostic value of PBL subsets in patients with advanced NSCLC who were treated with atezolizumab. Methods A total of 30 patients with advanced NSCLC treated with atezolizumab were selected as the observation group, and 30 healthy individuals were chosen as the control group during same period. Flow cytometry was used to detect lymphocyte subsets before and after treatment. The relationship between the changes of lymphocyte subsets and atezolizumab in the treatment of NSCLC was analyzed and calculated. Results Before treatment, compared with the control group, the number of CD3 + , CD4 + T, and CD4 + /CD8 + indexes in the observation group were significantly decreased, whereas the level of CD8 + was significantly increased. The number of CD3 + , CD4 + T, and CD4 + /CD8 + indexes gradually increased with the process of atezolizumab treatment, whereas the number of CD8 + T gradually decreased. After the 4 cycles, the number of CD3 + , CD4 + T, and CD4 + /CD8 + indexes were significantly increased, and the number of CD8 + was significantly decreased. In the observation group, 22 patients achieved partial response (PR)/stable disease (SD) and 8 patients achieved progressive disease (PD) after 4 cycles of atezolizumab treatment. Before treatment, there were no significant differences in the level of lymphocyte subsets between those who achieved PR/SD or PD. However, a significant difference in the level of lymphocyte subsets appeared after 4 cycles of atezolizumab treatment. Among the 22 patients who achieved PR/SD, the number of CD3 + , CD4 + T, and CD4 + /CD8 + indexes were significantly increased, whereas the number of CD8 + T lymphocytes was significantly decreased. Meanwhile, the 8 patients who achieved PD displayed different results. In addition, ROC curve combined detection of CD3 + , CD4 + , and CD8 + T [area under the curve (AUC) =0.9018, P<0.0001] showed good predictive ability for the efficacy of atezolizumab in advanced NSCLC. Conclusions Atezolizumab may alter the level of lymphocyte subsets in patients with advanced NSCLC, and the changes in lymphocyte subs...

show abstract

“…Some adverse drug reactions are associated with ICIs ( 32 , 33 ). In this study, no obvious adverse reactions occurred in all patients in the observation group.…”

Section: Discussionmentioning

confidence: 99%

Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study

Wang,

Zhu,

Zhou

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis

Cao,

Ding,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

IntroductionThe efficacy and safety of re-administration of immune checkpoint inhibitors (ICIs) in advanced solid tumors lacks consensus and is of great concern to clinicians. This study aimed to investigate the efficacy and adverse effects of ICIs rechallenges in advanced solid tumors.MethodsWe systematically searched the databases of PubMed, Embase, the Cochrane Library, and the China National Knowledge Infrastructure (CNKI), and screened the relevant literature according to the inclusion and exclusion criteria. Meanwhile, we conducted a meta-analysis of objective response rates (ORR), disease control rates (DCR), and immune-related adverse events (irAEs) for reuse of ICIs using Freeman-Tukey double arcsine transformation method.ResultsSixty eligible studies were included in the meta-analysis, and the results revealed that those who discontinued ICIs therapy and reused ICIs had an ORR of 21.6% [95% confidence interval (CI): 17.6, 25.7] and a DCR of 55.8% (95% CI: 50.0, 61.5). The overall incidence for grade ≥ 3 irAEs was 16.7% (95% CI: 11.8, 22.2). In the subgroup analysis, patients with renal cell carcinoma presented superior efficacy with an ORR of 30.9%, which was higher than that of melanoma (24.3%) and non-small cell lung cancer (NSCLC) (10.1%). Patients who have been treated with single-agent ICIs, re-treatment with a combination of ICIs directing different targets presents better outcomes, with ORR of 22.5% and DCR of 38%, respectively, compared with those patients who continue to use a single agent.ConclusionPatients with advanced solid tumors who have relapsed or progressed after prior treatment with ICIs may benefit from ICIs rechallenge, with a comparable incidence of grade ≥ 3 irAEs to those previously treated with ICIs.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023407409.

show abstract

Adverse drug reactions associated with immune checkpoint inhibitors: An exploratory nested case-control study in a historical cohort

Cited by 2 publications

References 26 publications

Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study

Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study

Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis

Contact Info

Product

Resources

About